Centiva Capital, LP Protalix Bio Therapeutics, Inc. Transaction History
Centiva Capital, LP
- $5.63 Billion
- Q2 2024
A detailed history of Centiva Capital, LP transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Centiva Capital, LP holds 130,332 shares of PLX stock, worth $136,848. This represents 0.0% of its overall portfolio holdings.
Number of Shares
130,332Holding current value
$136,848% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PLX
# of Institutions
70Shares Held
5.61MCall Options Held
103KPut Options Held
4.6K-
Israel Englander Millennium Management LLC | New York, Ny811KShares$851,7180.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny805KShares$844,8300.0% of portfolio
-
Goldman Sachs Group Inc New York, NY462KShares$485,0550.0% of portfolio
-
Northern Trust Corp Chicago, IL423KShares$444,3730.0% of portfolio
-
Gsa Capital Partners LLP London, X0401KShares$421,3060.03% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $52.2M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...